Global Non-melanoma Skin Cancer Market 2014-2018
Global Non-melanoma Skin Cancer Market 2014-2018 is the latest addition to Sandlerresearch.org industry research reports collection. The report is about 119 pages published in May-2014. Global Non-melanoma Skin Cancer Market 20142018 has been prepared based on an in-depth market analysis with inputs from industry experts. Non-melanoma skin cancer is one of the most common types of cancer in the world. It develops in the upper layers of the skin, but not in melanocytes. There are two types of non-melanoma skin cancer: BCC, which starts in the basal cells, and SCC, which starts in the squamous cells. BCC usually develops in the areas such as the head and neck, whereas SCC starts in the face, ears, neck, lips, and backs of the hands. These can also grow in wounds or chronic skin sores. Non-melanoma skin cancer is caused by unprotected and excessive exposure to UV radiation. It affects men more than women. It can be cured effectively if it is detected early. Treatment for non-melanoma skin cancer includes surgery, laser therapy, cryotherapy, creams, radiotherapy, chemotherapy, and PDT. Analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93 percent over the period 2013-2018. According to the report, the Global Non-melanoma Skin Cancer market is driven by several factors, of which the increasing prevalence of nonmelanoma skin cancer resulting from factors such as increased exposure to UV rays, ozone layer depletion, and genetic mutation is one of the major drivers. A current trend witnessed in the Global Non-melanoma Skin Cancer market is the use of combination therapies for the treatment of non-melanoma skin cancer. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and destruction of cancerous cells. For instance, radiation therapy may be used in combination with other therapies (chemotherapy and surgery) to treat aggressive or recurrent non-melanoma skin cancer. Patients that are non-reactive may react to combination therapy with 0.5 percent tretinoin cream with 5-FU cream. Thicker hypertrophic lesions should be treated first with cryosurgery, gentle curettage, or even primed with applications of tretinoin cream or short courses of topical diclofenac sodium. The combination is chosen according to the size of the tumor and risk of recurrence. Inquire for more information @ http://www.sandlerresearch.org/inquire-beforebuying?rname=17799 Report recognizes the following companies as the key players in Global Non-melanoma Skin Cancer Market: Elekta AB, F. Hoffmann-la Roche Ltd., iCAD Inc., Meda AB, Valeant